On 24 February, ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) reported Net loss for the fourth quarter of 2015 was $9.5 million, or $(0.07) per share, compared to a net loss of $10.4 million, or $(0.09) per share, for the fourth quarter of 2014.
ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) belongs to Healthcare sector. Its weekly performance is 26.35%. On last trading day company shares ended up at $9.59.
On 23 February, BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) reported total revenues decreased to $4.6 million from $5.4 million in the fourth quarter of 2014. The decrease resulted primarily from lower 2015 RAPIVAB royalty revenue, as well as lower collaborative revenue associated with BCX4430 development under contracts with the National Institute of Allergy and Infectious Diseases (NIAID) and the Biomedical Advanced Research and Development Authority (BARDA).
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) shares moved up 3.98% in last trading session and ended the day at $2.61. BCRX Gross Margin is 97.10% and its return on assets is -25.80%. BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) quarterly performance is -75.54%.
Smith & Wesson (NASDAQ: SWHC) reported Q3 EPS of $0.59, $0.20 better than the analyst estimate of $0.39. Revenue for the quarter came in at $210.8 million versus the consensus estimate of $174.93 million. GUIDANCE: Smith & Wesson sees Q4 2016 EPS of $0.51-$0.53, versus the consensus of $0.47. Smith & Wesson sees Q4 2016 revenue of $210-215 million, versus the consensus of $195.1 million. Smith & Wesson sees FY2016 EPS of $1.68-$1.70, versus the consensus of $1.55. Smith & Wesson sees FY2016 revenue of $712-717 million, versus the consensus of $703.5 million.
On 03 March, Smith & Wesson Holding Corporation (NASDAQ:SWHC) shares moved up 0.47% and was closed at $25.40. SWHC EPS growth in last 5 year was 19.50%. Smith & Wesson Holding Corporation (NASDAQ:SWHC) year to date (YTD) performance is 15.56%.
Derma Sciences, Inc. (NASDAQ: DSCI) announces that WPS Government Health Administrators (WPS), a Medicare Administrative Contractor (MAC) for Part B serving States primarily in the Midwest and National MAC for Jurisdiction 5, has retired its local coverage determination (LCD) for cellular or tissue-based products (CTPs) effective March 1, 2016. WPS now considers CTPs to be a commonly used tool for treating chronic wounds. As a result, the Company’s AMNIOEXCEL® Amniotic Allograft Membrane (AMNIOEXCEL®) will be considered for coverage with appropriate documentation of medical necessity as a second-line therapy following standard wound care treatment.
Derma Sciences Inc. (NASDAQ:DSCI) ended the last trading day at $3.20. Company weekly volatility is calculated as 8.09% and price to cash ratio as 1.67. Derma Sciences Inc. (NASDAQ:DSCI) showed a weekly performance of -2.74%.
Sanofi (NYSE: SNY) and its specialty care global business unit Sanofi Genzyme today presented data from NEO1, its Phase 1/2 clinical study evaluating the investigational novel enzyme replacement therapy neoGAA in 24 patients with late-onset Pompe disease. The safety and efficacy data from this study, which were presented at WORLDSymposium 2016 in San Diego, CA, support further development of the therapy. Sanofi Genzyme plans to begin enrolling patients in a pivotal Phase 3 trial for neoGAA in Q2 2016.
Sanofi SA (ADR) (NYSE:SNY) shares moved down -1.42% in last trading session and ended the day at $39.62. SNY Gross Margin is 68.70% and its return on assets is 9.50%. Sanofi SA (ADR) (NYSE:SNY) quarterly performance is -10.06%.